Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma Patients
NCT01990859 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20
Last updated 2016-03-14
Summary
The purpose of this study is to assess the safety of Ipilimumab monotherapy in Japanese subjects with advanced melanoma
Conditions
Interventions
- BIOLOGICAL
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 20 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-12-31
- Primary Completion
- 2014-05-31
- Completion
- 2015-02-28
Countries
- Japan
Study Locations
More Related Trials
-
A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma
NCT02905266 ·Status: COMPLETED ·Phase: PHASE3
-
Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma
NCT01489059 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
NCT01696045 ·Status: TERMINATED ·Phase: PHASE2
-
A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma
NCT01654692 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma
NCT01245556 ·Status: COMPLETED ·Phase: PHASE1
-
Observational Study of Nivolumab Monotherapy or in Combination With Ipilimumab in Participants With Advanced Melanoma and in Participants With Adjuvant Nivolumab Therapy
NCT02990611 ·Status: COMPLETED
-
Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab
NCT01515189 ·Status: COMPLETED ·Phase: PHASE3
-
A Pilot Study of Ipilumimab and Radiation in Poor Prognosis Melanoma
NCT01996202 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma
NCT01927419 ·Status: COMPLETED ·Phase: PHASE2
-
Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
NCT01708941 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma
NCT01604889 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Ipilimumab + Temozolomide in Metastatic Melanoma
NCT01119508 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma
NCT02970981 ·Status: COMPLETED ·Phase: PHASE2
-
Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma
NCT01740297 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of Radiotherapy Administered in Combination With Ipilimumab in Patients With Unresectable Stage III or Stage IV Advanced Malignant Melanoma
NCT01557114 ·Status: TERMINATED ·Phase: PHASE1
-
Trial of Ipilimumab After Isolated Limb Perfusion, in Patients With Metastases Melanoma
NCT02094391 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
NCT00636168 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma
NCT01709162 ·Status: TERMINATED ·Phase: PHASE2
-
Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)
NCT01783938 ·Status: COMPLETED ·Phase: PHASE2
-
Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma
NCT00803374 ·Status: WITHDRAWN ·Phase: PHASE1
-
An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself
NCT02320058 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma
NCT04007588 ·Status: WITHDRAWN ·Phase: PHASE2
-
A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma.
NCT02068196 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma
NCT00289640 ·Status: COMPLETED ·Phase: PHASE2
-
Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
NCT03021460 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1